<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20181022041419N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-01-12</date_registration>
      <primary_sponsor>Oroumia University of Medical Sciences</primary_sponsor>
      <public_title>The effects of e-learning of preventing medication errors on knowledge, attitude and performance of nursing students internships in Pediatrics units Faculty of Nursing and Midwifery in 2015</public_title>
      <acronym></acronym>
      <scientific_title>The effects of e-learning of preventing medication errors on knowledge, attitude and performance of nursing students internships in Pediatrics units</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2016-01-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/35876</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Education/Guidance, Randomization description: Random method and description of each method: simple randomizationRandom unit: IndividualRandomization Tool: Like a random numbered tableHow to make a random sequence: The first two groups were randomized in the control group and the subsequent groups in the intervention group.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Drug errors in the pediatric units.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In the intervention group, e-learning, drug errors and drug misuse prevention guidelines were performed 3 weeks before the beginning of the internship. E-learning intervention was conducted in 9 sessions of 60 minutes three times a week (Saturday, Monday and Wednesday) online with the creation of a training channel for group discussion and exchange of comments and another channel was only for providing training in the telegram. It should be noted that e-learning was conducted collectively (10 people) for each group of interns. Student attendance at each training session was reviewed and approved. To review the contents of the sessions in the first 15 minutes of each session, questions and answers were made and at the end of each session, the next meeting materials were sent to students in PDF format and asked them to go to the channel and learn the contents of the course. It should be noted that the answers to some of the questions related to the problems raised on the same day were also answered to the students. The contents of the training were collected from authored pharmacology books and the patient and nursing Guidelines for nursing and physicians approved by both physicians and nursing practitioners.The contents of the training were compiled from authored pharmacology books  and nurse-patient safety guidelines approved by nursing doctors and physicians that include: at the first week: Definition of patient safety, drug error and its prevalence, types of drug errors, causes of drug misconduct, at the second week: Identifying high-risk drugs in the pediatric ward and the necessary notes on registration and enforcement, familiarity with the drug registration system, reporting in the event of a drug mistake, and at the third week: the recognition of common drugs in the pediatric ward based on their common illnesses (6 categories: Drugs for heart failure and respiratory problems, important antibiotics, electrolytes, corticosteroids and anti-inflammatory drugs tracks) and provide the necessary guidance on their applied nursing care. Intervention 2: Control group: The routine trainings were received by the same trainer.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Individual data is shared by the participants, and only part of the original outcome can be shared.

When:
Starting the access period from 2019

To whom:
Researchers working in academic and scientific institutions

Conditions:
Send a request for access to the data or documentation via email

Where to obtain:
Sima Pourteimour
simapure@yahoo.com

How to obtain:
At least a week

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sima Pourteimour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Nazlou Campus Building Faculty of Nursing and Midwifery, 11 km Sero, Urmia, West Azarbaijan, Iran</address>
        <city>Urmia</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5756115111</zip>
        <telephone>+98 44 3275 4963</telephone>
        <email>simapure@yahoo.com</email>
        <affiliation>Oroumia University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Sima Pourteimour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Nazlou Campus Building Faculty of Nursing and Midwifery, 11 km Sero, Urmia, West Azarbaijan, Iran</address>
        <city>Urmia</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5718673533</zip>
        <telephone>+98 44 3275 4963</telephone>
        <email>simapure@yahoo.com</email>
        <affiliation>Oroumia University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Choosing a child's apprenticeship unit
At least 1 unit of apprenticeship has been completed in the neonatal department.</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Do not attend e-learning at least 2 times
Do not tend to participate in this study.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In the intervention group, e-learning, drug errors and drug misuse prevention guidelines were performed 3 weeks before the beginning of the internship. E-learning intervention was conducted in 9 sessions of 60 minutes three times a week (Saturday, Monday and Wednesday) online with the creation of a training channel for group discussion and exchange of comments and another channel was only for providing training in the telegram. It should be noted that e-learning was conducted collectively (10 people) for each group of interns. Student attendance at each training session was reviewed and approved. To review the contents of the sessions in the first 15 minutes of each session, questions and answers were made and at the end of each session, the next meeting materials were sent to students in PDF format and asked them to go to the channel and learn the contents of the course. It should be noted that the answers to some of the questions related to the problems raised on the same day were also answered to the students. The contents of the training were collected from authored pharmacology books and the patient and nursing Guidelines for nursing and physicians approved by both physicians and nursing practitioners.The contents of the training were compiled from authored pharmacology books  and nurse-patient safety guidelines approved by nursing doctors and physicians that include: at the first week: Definition of patient safety, drug error and its prevalence, types of drug errors, causes of drug misconduct, at the second week: Identifying high-risk drugs in the pediatric ward and the necessary notes on registration and enforcement, familiarity with the drug registration system, reporting in the event of a drug mistake, and at the third week: the recognition of common drugs in the pediatric ward based on their common illnesses (6 categories: Drugs for heart failure and respiratory problems, important antibiotics, electrolytes, corticosteroids and anti-inflammatory drugs tracks) and provide the necessary guidance on their applied nursing care.</i_keyword>
      <i_keyword>Control group: The routine trainings were received by the same trainer.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Awareness survey is divided into three groups of weak, moderate and good, with grades 26 to 60 poor knowledge, 61 to 95 average knowledge, and 96-130 good knowledge. Timepoint: Before internship, after internship. Method of measurement: Self-made knowledge questionnaire to determine the prevention of drug errors.</prim_outcome>
      <prim_outcome>The attitude is divided into two groups of positive and negative attitude that the scores above 60 were positive attitudes and less than 60 negative attitudes were considered. Timepoint: Before internship, after internship. Method of measurement: Self-made attitude questionnaire to determine the prevention of drug errors.</prim_outcome>
      <prim_outcome>Performance is divided into three categories: Weak, Moderate, and Good, with grades 30 to 80, poor performance, grades 81 to 131, moderate performance and 132 to 150 good performance. Timepoint: Before internship, after internship. Method of measurement: Self-made checklist to determine performance for preventing drug errors.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Oroumia University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2015-10-28</approval_date>
        <contact_name>Ethics committee of Urmia University of Medical Sciences</contact_name>
        <contact_address>Setad of Urmia university of medical science, Resalat Ave, Urmia city Urmia West Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
